Natriuretic Peptide Levels and Stages of Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction. 2023

Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
Laboratory of Experimental Cardiology, Division Heart & Lungs, Utrecht University Medical Centre, 3584 CX Utrecht, The Netherlands.

In heart failure with preserved ejection fraction (HFpEF), natriuretic peptide (NP) levels are frequently lower. In several trials, the outcome differed between patients with low and high NP levels. This suggests that NP could be used to identify distinct stages of left ventricular (LV) remodeling and myocardial tissue composition. This study investigated cardiac remodeling/dysfunction and myocardial tissue characteristics assessed by echocardiography and cardiac magnetic resonance (CMR) in HFpEF patients in relation to NP levels. Clinical and echocardiographic data of 152 HFpEF patients were derived from outpatient visits. A total of 71 HFpEF patients underwent CMR-derived T1-mapping. Multivariable regression analyses were performed to examine the association of NT-proBNP categories (</> median) and NT-proBNP as continuous variable with echocardiography and CMR-derived T1-mapping. Mean age was 71 ± 9, 93% of patients were women and median NT-proBNP was 195 pg/mL, with 35% of patients below the diagnostic cut-off value (<125 pg/mL). Patients with high NT-proBNP had comparable LV systolic function and LV relaxation but significantly worse LV stiffness and left atrial function compared with patients with low NT-proBNP. Higher NT-proBNP was significantly associated with higher LV stiffness and extracellular volume fraction (ECV) (β = 1.82, 95% CI: 0.19;3.44, p = 0.029). Higher NT-proBNP levels identify HFpEF patients with worse LV stiffness because of more severe myocardial extracellular matrix remodeling, representing an advanced stage of HFpEF.

UI MeSH Term Description Entries

Related Publications

Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
October 2013, Praxis,
Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
September 2019, Der Internist,
Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
August 2022, Circulation,
Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
July 2012, The American journal of cardiology,
Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
April 2024, Therapeutische Umschau. Revue therapeutique,
Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
January 2012, Kardiologiia,
Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
August 2013, Journal of the American College of Cardiology,
Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
January 2012, Circulation journal : official journal of the Japanese Circulation Society,
Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
December 2017, European journal of heart failure,
Elisa Dal Canto, and Marielle Scheffer, and Kirsten Kortekaas, and Annet Driessen-Waaijer, and Walter J Paulus, and Loek van Heerebeek
April 2021, American journal of physiology. Heart and circulatory physiology,
Copied contents to your clipboard!